Unresolved
We still don’t know whether anyone at this organisation has actually used this technology — zero lived-experience observations exist.
Not yet answered
What are we missing?
HealthAratus Intelligence
Grail
GrailGrail Intelligence
What the accumulated evidence, deployment record and lived experience actually show.
Intelligence lenses
Four ways of interrogating the same reality. Each changes the question, not the subject.
What is becoming different about Grail over time?
Not enough activity across time yet to describe how this reality has moved.
What we know · what we don’t
Everything here is open to being corrected by someone who has seen it first-hand.
What we still don’t know
Nobody has answered these yet. Your experience can help us understand what is happening.
Matters of record
Settled elsewhere. Context for reading the above, not something practice can confirm.
- 1 public external signal(s) across 1 source(s).Recorded by HealthAratus
Tool intelligence
What HealthAratus understands
HealthAratus currently understands Grail through company records and external market activity.
- Category
- imaging_diagnostics
What HealthAratus is still learning
HealthAratus is beginning to understand Grail. As evidence and experience accumulate, what remains unclear will be stated here.
Evidence & claims
What this is built on
The material the questions above were built from, with its attribution.
Galleri is a multi-cancer early detection test that uses a blood draw to identify DNA patterns associated with over 50 cancer types. It is intended to assist in the early identification of cancer, including types without standard screening.According to Grail
What Grail states
The vendor’s own claims. Testable where practice can actually test them.
Stated capability
The test detects cancer signals for over 50 cancer types from a single blood draw.
According to Grail
Does this change your workflow?
Independent and public evidence
Found in public sources. Not a clinician’s experience, and never presented as one.
Reported outcome
Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail
According to MedCity News
Are you seeing this result?
Company participation
Not yet verified
A record of the reality forming around this technology already exists. No representative of the company has verified participation yet.
Claim your company profileReference
The stable facts, for interpreting everything above.
Overview
What it does
- Product Overview: GRAIL's Galleri is a multi-cancer early detection (MCED) blood test designed to detect signals from more than 50 types of cancers, including those lacking recommended screening tests.…
Vendor & external product information, not independently verified by HealthAratus
Where it's used
Deployed in mixed settings
Parent Company
Grailvendor
How the reality here has changed
Not enough recorded activity across time yet to describe how the reality here has moved. As accounts of Grail accumulate, this becomes a record of how the reality moved rather than a snapshot of one moment.
Connected intelligence
Category intelligence